Hemostemix Inc. (CVE:HEM – Get Free Report) rose 31% during trading on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares traded hands during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a market cap of C$27.69 million, a price-to-earnings ratio of -5.54 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock has a 50-day moving average price of C$0.20 and a 200 day moving average price of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
